Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death worldwide and has an increasing incidence in the United States.1 Prognosis for patients with HCC largely depends on tumor stage at diagnosis, with curative options only available for patients diagnosed at an early stage.2 Surveillance at 6-month intervals is recommended in patients with cirrhosis to detect HCC at an early stage.3 Despite the availability of efficacious surveillance tests, only 40% of patients with HCC are diagnosed at an early stage nationally.4,5 Tumor stage at diagnosis can be influenced by several factors in clinical practice, including low screening rates and delays in follow-up of abnormal screening tests.6-10
Underuse and/or delays in treatment have also been described as a potential cause of poor cancer outcomes.11-16 The transition from diagnosis to treatment is a complex process in clinical practice, with several steps that are prone to delays and/or failure. Providers must determine the optimal treatment and refer patients to the appropriate provider, the health care system must schedule these appointments, and patients must adhere to these recommendations. This process may be particularly difficult in patients with HCC given primary care providers’ lack of familiarity with the wide array of potential treatment options, each delivered by different providers. For patients diagnosed with HCC, delays as little as 3 months in therapeutic follow-up can allow for significant tumor growth and potentially lead to decreased options for effective treatment.17
Although prior studies have shown underuse of appropriate treatment among patients with HCC, no studies have provided an in-depth analysis of the prevalence and clinical impact of therapeutic delays.18,19 The primary goals of this study were to characterize and identify factors associated with underuse and delays in treatment among a cohort of patients with HCC.
The authors have disclosed that they have no financial interests, arrangements, affiliations, or commercial interests with the manufacturers of any products discussed in this article or their competitors. This work was conducted with support from UT-STAR, NIH/NCATS Grant Number KL2 TR000453, NIH/NCATS Grant UL1-TR000451, and the ACG Junior Faculty Development Award awarded to Dr. Singal. Dr. Waljee’s research is funded by a VA HSR&D CDA-2 career development award 1IK2HX000775. The content is solely the responsibility of the authors and does not necessarily represent the official views of UT-STAR, the University of Texas Southwestern Medical Center and its affiliated academic and health centers, the National Center for Advancing Translational Sciences, the Veterans Affairs, or the National Institutes of Health.
El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007;132:2557–2576.
Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009;27:1485–1491.
Singal A, Volk ML, Waljee A et al.. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther 2009;30:37–47.
Davila JA, Morgan RO, Richardson PA et al.. Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States. Hepatology 2010;52:132–141.
Singal AG, Conjeevaram HS, Volk ML et al.. Effectiveness of hepatocellular carcinoma surveillance in patients with cirrhosis. Cancer Epidemiol Biomarkers Prev 2012;21:793–799.
Singal AG, Nehra M, Huet B et al.. Detection of hepatocellular carcinoma at advanced stages among patients in the HALT-C trial: where did surveillance fail? Am J Gastro 2013;108:425–432.
Singal AG, Yopp A, Skinner CS et al.. Utilization of hepatocellular carcinoma surveillance among american patients: a systematic review. J Gen Intern Med 2012;27:861–867.
Singal AG, Yopp AC, Gupta S et al.. Failure rates in the hepatocellular carcinoma surveillance process. Cancer Prev Res (Phila) 2012;5:1124–1130.
Fahmy NM, Mahmud S, Aprikian AG. Delay in the surgical treatment of bladder cancer and survival: systematic review of the literature. Eur Urol 2006;50:1176–1182.
Korsgaard M, Pedersen L, Sorensen HT, Laurberg S. Delay of treatment is associated with advanced stage of rectal cancer but not of colon cancer. Cancer Detect Prev 2006;30:341–346.
Langenbach MR, Schmidt J, Neumann J, Zirngibl H. Delay in treatment of colorectal cancer: multifactorial problem. World J Surg 2003;27:304–308.
McLaughlin JM, Anderson RT, Ferketich AK et al.. Effect on survival of longer intervals between confirmed diagnosis and treatment initiation among low-income women with breast cancer. J Clin Oncol 2012;30:4493–4500.
Richards MA, Westcombe AM, Love SB et al.. Influence of delay on survival in patients with breast cancer: a systematic review. Lancet 1999;353:1119–1126.
Ashing-Giwa KT, Gonzalez P, Lim JW et al.. Diagnostic and therapeutic delays among a multiethnic sample of breast and cervical cancer survivors. Cancer 2010;116:3195–3204.
Kubota K, Ina H, Okada Y, Irie T. Growth rate of primary single hepatocellular carcinoma: determining optimal screening interval with contrast enhanced computed tomography. Dig Dis Sci 2003;48:581–586.
Tan D, Yopp A, Beg MS et al.. Meta-analysis: underutilisation and disparities of treatment among patients wtih hepatocellular carcinoma in the United States. Aliment Pharmacol Ther, in press.
Shah SA, Smith JK, Li Y et al.. Underutilization of therapy for hepatocellular carcinoma in the medicare population. Cancer 2011;117:1019–1026.
Cillo U, Vitale A, Grigoletto F et al.. Prospective validation of the Barcelona Clinic Liver Cancer staging system. J Hepatol 2006;44:723–731.
Singal AG, Tiro JA, Gupta S. Improving hepatocellular carcinoma screening: applying lessons from colorectal cancer screening. Clin Gastroenterol Hepatol 2013;11:472–477.
Davila JA, Kramer JR, Duan Z et al.. Referral and receipt of treatment for hepatocellular carcinoma in United States veterans: effect of patient and nonpatient factors. Hepatology 2013;57:1858–1868.
Artinyan A, Mailey B, Sanchez-Luege N et al.. Race, ethnicity, and socioeconomic status influence the survival of patients with hepatocellular carcinoma in the United States. Cancer 2010;116:1367–1377.
Sloane D, Chen H, Howell C. Racial disparity in primary hepatocellular carcinoma: tumor stage at presentation, surgical treatment and survival. J Natl Med Assoc 2006;98:1934–1939.
Davila JA, El-Serag HB. Racial differences in survival of hepatocellular carcinoma in the United States: a population-based study. Clin Gastroenterol Hepatol 2006;4:104–110; quiz 4-5.
Siegel AB, McBride RB, El-Serag HB et al.. Racial disparities in utilization of liver transplantation for hepatocellular carcinoma in the United States, 1998-2002. Am J Gastroenterol 2008;103:120–127.